SubHero Banner
Text

Nerlynx (neratinib) – New drug approval

July 17, 2017 – The FDA announced the approval of Puma Biotechnology’s Nerlynx (neratinib) for the extended adjuvant treatment of adult patients with early stage human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer, to follow adjuvant Herceptin® (trastuzumab) based therapy.

Download PDF